Montrouge, France, September 2, 2022
DBV Technologies to Present at Upcoming Investor Conferences
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, DBV Technologies, will participate in upcoming investor conferences in September.
Wells Fargo Healthcare Conference
September 7 – 9, 2022 | In-Person Conference | Boston, MA
Daniel Tassé will be on-site in Boston on Thursday, September 8, 2022 to participate in a fireside chat at 4:20 p.m. ET.
H.C. Wainwright 24rd Annual Global Investment Conference
September 12 – 14, 2022 | Hybrid In-Person and Virtual Conference | New York, NY
Daniel Tassé will be on-site in New York on Monday, September 12, 2022 for a company presentation at 11:00 a.m. ET.
A webcast of each engagement, the fireside chat and company presentation, will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/.
A replay of both engagements will also be available on DBV Technologies’ website after the events conclude.
About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com
Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com
Attachment
Boards and executive buyers are raising the 2026 bar for all product and service rankings…
Boards and executive buyers are raising the 2026 bar for all product and service rankings…
Tampa based Celebrity Board-Certified Plastic Surgeon Dr. Meegan Gruber expands an interactive approach that allows…
Clemson University and Nordic Wellness have launched a pioneering partnership tackling the student mental health…
Telehealth Platform Offers Compounded GLP-1 Injections and Oral Tablets at $299/Month With No Contract as…
MINNEAPOLIS, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (“Vireo”) (CSE: VREO; OTCQX: VREOF)…